Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.61 |
| ▸ | HTR3B | O95264 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240000 | 1.00 | HTR3E (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12892626 | 1.00 | HTR3E (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30208090 | 1.00 | HTR3E (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL20139242 | 0.98 | HTR3E (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5632352 | 0.83 | ADRB1 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5632344 | 0.83 | ADRB1 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30005135 | 0.83 | ADRB1 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL315161 | 0.83 | ADRB1 (0.63) | ADRB1NOTUMKHKALOX5MAPT | |
| SCHEMBL8534451 | 0.82 | ADRB1 (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8109027 | 0.81 | KHK (0.50) | ADRB1KHKBCL2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| CN-1989106-B | N-hydroxyamide derivatives and their use | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-7879836-B2 | treatment of hyperphagia comprising the administering 1-(3-chlorophenyl)-3-alkylpiperazine derivatives such as 1-(3-chlorophenyl)-3-ethylpiperazine; anorexigenic agents | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-02-01 | — | — | US | disclosed |
| US-7879836-B2 | treatment of hyperphagia comprising the administering 1-(3-chlorophenyl)-3-alkylpiperazine derivatives such as 1-(3-chlorophenyl)-3-ethylpiperazine; anorexigenic agents | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-02-01 | — | — | US | disclosed |
| CN-1046281-C | Pharmacologically active enantiomers and process for their preparation | ANGELINI RICERCHE SPA (IT) | 1999-11-10 | — | — | CN | disclosed |
| US-5973150-A | PHARMACOLOGICAL PROFILE SIMILAR TO THAT OF TRAZODONE BUT ALSO HAVE SOME ADVANTAGES SUCH AS, FOR EXAMPLE, A REDUCED AFFINITY FOR ADRENERGIC RECEPTORS. | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1999-10-26 | — | — | US | disclosed |
| CN-1215052-A | Pharmacollogically active enantiomers and method for their preparation | ANGELINI RICERCHE SPA (IT) | 1999-04-28 | — | — | CN | disclosed |
| CN-1215053-A | Pharmacologically active enantiomers and method for their preparation | ANGELINI RICERCHE SPA (IT) | 1999-04-28 | — | — | CN | disclosed |
| US-5817815-A | 2-(3-(4-(3-CHLOROPHENYL)-1-(2-METHYL)-PIPERAZINYL)PROPYL)-1,2, 4-TRIAZOLO(4.3-A)PYRIDINE-3(2H)-ONE, ANALGESICS | ANGELINI RICERCHE S.P.A. SOCIETA CONSORTILE (IT) | 1998-10-06 | — | — | US | disclosed |
| US-5741907-A | CYCLIZATION; SALT FORMATION; SEPARATION | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1998-04-21 | — | — | US | disclosed |
| EP-0707587-B1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE SPA (IT) | 1997-10-01 | — | — | EP | disclosed |
| CN-1129939-A | Pharmacologically active enantiomers | ANGELINI FRANCESCO IST RICERCA (IT) | 1996-08-28 | — | — | CN | disclosed |
| EP-0707587-A1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE SPA (IT) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001354-A1 | PHARMACOLOGICALLY ACTIVE ENANTIOMERS | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | HTR3E 497/4885HTR3B 307/4885HTR3A 305/4885 |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | HTR3E 1908/4885HTR3B 1285/4885HTR3A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.